Medical Sciences Director
Pubblicato il 12-10-2026 - Quetzal in Italia
Quetzal Therapeutics is a biopharmaceutical company focused on the development of treatment for rare diseases including hematologic malignancies. The company’s lead product is QTX-2101, a novel paradigm for treating patients with Acute Promyelocytic Leukemia (APL) for which the company initiated a Phase III clinical trial in December 2025. Quetzal is also developing a pre-clinical asset QTX-2102, an advanced, next-generation antifungal and antiparasitic therapy designed to enhance efficacy while minimizing toxicity. Contractor Medical Science Liaison (MSL) – Italy/Germany Territory
Haematology / Oncology – Phase 3 Clinical Trial Support
We are seeking an experienced contractor Medical Science Liaison (MSL) to support a multinational Phase 3 haematology/oncology clinical trial across Italy and Germany. This field-based role will focus on scientific engagement with investigators and treatment centres, supporting trial awareness, operational engagement, and high-quality scientific exchange within a compliant framework.
Approximately 70–80% field-focused activity expected.
Develop and maintain scientific relationships with investigators, referral centres, and relevant healthcare professionals
Support scientific engagement around an ongoing Phase 3 haematology clinical trial
Deliver high-quality, non-promotional scientific exchange in compliance with applicable regulations and company SOPs
Ensure timely and accurate documentation of activities and reporting of adverse events/product complaints in accordance with pharmacovigilance requirements
Work cross-functionally with Medical Affairs, Clinical Operations, and other internal stakeholders
Required Qualifications & Experience
Advanced scientific or healthcare degree (PharmD, PhD, MD, MSc or equivalent)
Prior experience as a field-based MSL within oncology or haematology
Strong scientific acumen and ability to communicate complex clinical data effectively
Experience developing relationships with academic investigators and